AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19104789 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 16953381 — intervention group
Group type: EXPERIMENTAL
Intervention: IM aripiprazole 9.75 mg
Number of subjects: 448
Study 16953381 — intervention group
Group type: EXPERIMENTAL
Intervention: IM haloperidol 6.5 mg
Number of subjects: 448
Study 16953381 — intervention group
Group type: COMPARATOR
Intervention: IM placebo
Number of subjects: 448
Study 15216689 — intervention group
Group type: EXPERIMENTAL
Intervention: Coagulation (Group A) - scalpel for first half, coagulation-fulgurate for second half
Number of subjects: 73
Study 15216689 — intervention group
Group type: EXPERIMENTAL
Intervention: Cut mode (Group B) - scalpel for first half, blend cut mode for second half
Number of subjects: 73
Study 10902797 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin levels in serum (30.3 +/- 14.8 ng/mL)
Number of subjects: 28
Study 10902797 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin levels in peritoneal fluid (PF) (35.9 +/- 17.4 ng/mL)
Number of subjects: 28
Study 10902797 — intervention group
Group type: COMPARATOR
Intervention: Control group serum leptin levels (15.6 +/- 8.4 ng/mL)
Number of subjects: 28
Study 10902797 — intervention group
Group type: COMPARATOR
Intervention: Control group PF leptin levels (17.5 +/- 7.2 ng/mL)
Number of subjects: 28
Study 10902797 — intervention group
Group type: EXPERIMENTAL
Intervention: Regression equations relating leptin to body mass index
Number of subjects: 28
Study 10902797 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin levels in earlier stages of endometriosis
Number of subjects: 28
Study 9017127 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenestrated prosthesis
Number of subjects: 32
Study 9017127 — intervention group
Group type: COMPARATOR
Intervention: Small‐Carrion implants
Number of subjects: 32
Study 8326334 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (2 mg/kg/day)
Number of subjects: 40
Study 8326334 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 40
Study 3449560 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacist consultation (experimental group)
Number of subjects: 60
Study 3449560 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacokinetically based serum level measure
Number of subjects: 60
Study 3449560 — intervention group
Group type: COMPARATOR
Intervention: Existing measures
Number of subjects: 60
Study 29588232 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg slow-release propranolol daily for 7 days
Number of subjects: 64
Study 29588232 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg slow-release propranolol
Number of subjects: 64
Study 29588232 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 27590374 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic capsules containing Lactobacillus rhamnosus GR-1 and Lactobacillus reuteri RC-14
Number of subjects: 110
Study 27590374 — intervention group
Group type: COMPARATOR
Intervention: Placebo capsules
Number of subjects: 110
Study 25230995 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Years Education Program (EYEP)
Number of subjects: 90
Study 25230995 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 90
Study 23785525 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment with annual mass treatment for three years (3×)
Number of subjects: 48
Study 23785525 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment with stopping rule (SR)
Number of subjects: 48
Study 23785525 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced treatment with annual mass treatment for three years (3×)
Number of subjects: 48
Study 23785525 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced treatment with stopping rule (SR)
Number of subjects: 48
Study 23785525 — intervention group
Group type: COMPARATOR
Intervention: One round of mass drug administration (MDA)
Number of subjects: 48
Study 23785525 — intervention group
Group type: COMPARATOR
Intervention: Three rounds of mass drug administration (MDA)
Number of subjects: 48
Study 21038650 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir + Yidu Recipe (YDR) for 6 months
Number of subjects: 57
Study 21038650 — intervention group
Group type: COMPARATOR
Intervention: Entecavir alone for 6 months
Number of subjects: 57
Study 21038650 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir + Yidu Recipe (YDR)
Number of subjects: 57
Study 21038650 — intervention group
Group type: COMPARATOR
Intervention: Entecavir alone
Number of subjects: 57
Study 20633462 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacopuncture with chondro-protector Alflutop
Number of subjects: 0
Study 20633462 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacopuncture
Number of subjects: 0
Study 16898996 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-week intervention group (received intervention for two consecutive 10-week periods)
Number of subjects: 77
Study 16898996 — intervention group
Group type: EXPERIMENTAL
Intervention: 10-week intervention group (received intervention only during the second 10 weeks)
Number of subjects: 77
Study 16898996 — intervention group
Group type: COMPARATOR
Intervention: Control group (not receiving the intervention during the first 10 weeks)
Number of subjects: 77
Study 12918544 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel antiplatelet and anticoagulant strategies
Number of subjects: 0
Study 12918544 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel agents targeting haemostatic pathways
Number of subjects: 0
Study 12918544 — intervention group
Group type: EXPERIMENTAL
Intervention: New compounds
Number of subjects: 0
Study 10802077 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g intravenous cefazolin
Number of subjects: 441
Study 10802077 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 441
Study 8796665 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.075 mmol/kg gadoterate meglumine
Number of subjects: 40
Study 8796665 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.100 mmol/kg gadoterate meglumine
Number of subjects: 40
Study 8796665 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.150 mmol/kg gadoterate meglumine
Number of subjects: 40
Study 8796665 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.200 mmol/kg gadoterate meglumine
Number of subjects: 40
Study 8796665 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses (0.075, 0.100, 0.150, 0.200 mmol/kg)
Number of subjects: 40
Study 1347091 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intervention (D)
Number of subjects: 90
Study 1347091 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet plus cholestyramine (DC)
Number of subjects: 90
Study 1347091 — intervention group
Group type: COMPARATOR
Intervention: Usual care (U, control)
Number of subjects: 90
Study 1347091 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (D and DC)
Number of subjects: 90
Study 6186457 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate (placebo, low, medium, high doses)
Number of subjects: 21
Study 30534955 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-Rich Plasma (PRP)
Number of subjects: 10
Study 30534955 — intervention group
Group type: COMPARATOR
Intervention: Normal Saline
Number of subjects: 10
Study 28114979 — intervention group
Group type: EXPERIMENTAL
Intervention: Short duration antibiotic therapy (8 days)
Number of subjects: 34
Study 28114979 — intervention group
Group type: COMPARATOR
Intervention: Prolonged antibiotic therapy (15 days)
Number of subjects: 34
Study 26649908 — intervention group
Group type: COMPARATOR
Intervention: Epidural ropivacaine 0 mg (Control)
Number of subjects: 28
Study 26649908 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine 50 mg
Number of subjects: 28
Study 26649908 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine 100 mg
Number of subjects: 28
Study 26649908 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural ropivacaine 150 mg
Number of subjects: 28
Study 24937440 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 10mg
Number of subjects: 848
Study 24937440 — intervention group
Group type: EXPERIMENTAL
Intervention: Tanezumab 20mg
Number of subjects: 848
Study 21975821 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice-based screening using PHQ-2 followed by PHQ-9 for screen positives
Number of subjects: 10929
Study 21975821 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline assessment for patients with probable major depression
Number of subjects: 10929
Study 19066345 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional lactate-based peritoneal dialysis solution (D)
Number of subjects: 26
Study 19066345 — intervention group
Group type: COMPARATOR
Intervention: Bicarbonate/lactate-based peritoneal dialysis solution (P)
Number of subjects: 26
Study 17599581 — intervention group
Group type: EXPERIMENTAL
Intervention: Surface electromyography (sEMG) evaluation post-tonsillectomy
Number of subjects: 40
Study 14746947 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) therapy
Number of subjects: 35
Study 14746947 — intervention group
Group type: COMPARATOR
Intervention: No-treatment group
Number of subjects: 35
Study 12626209 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormone Replacement Therapy (HRT)
Number of subjects: 0
Study 12626209 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 10188748 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder width stance with low load (60% 1RM)
Number of subjects: 9
Study 10188748 — intervention group
Group type: EXPERIMENTAL
Intervention: Shoulder width stance with high load (75% 1RM)
Number of subjects: 9
Study 10188748 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow stance (75% shoulder width) with low and high loads
Number of subjects: 9
Study 10188748 — intervention group
Group type: EXPERIMENTAL
Intervention: Wide stance (140% shoulder width) with low and high loads
Number of subjects: 9
Study 10188748 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascent phase of squat
Number of subjects: 9
Study 7596125 — intervention group
Group type: EXPERIMENTAL
Intervention: SIN-1 (1.0 micrograms/kg/min)
Number of subjects: 23
Study 7596125 — intervention group
Group type: COMPARATOR
Intervention: ISDN (highest dose)
Number of subjects: 23
Study 2397543 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine (TCM) treatment with herbs: Bupleurum chinense, Scutellaria baicalensis, Astragalus membranaceus, Codonopsis pilosula, Ligustrum lucidum, Lophatherum gracile, and thread of ivory, for 1-3 courses of treatment lasting one month each.
Number of subjects: 100
Study 2397543 — intervention group
Group type: COMPARATOR
Intervention: Western Medicine (WM) treatment with retalin 5-15 mg twice daily, for 1-3 courses of treatment lasting one month each.
Number of subjects: 100
Study 31063 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 5 mg
Number of subjects: 18
Study 31063 — intervention group
Group type: COMPARATOR
Intervention: Diazepam 10 mg
Number of subjects: 18
Study 31063 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 18
Study 28647684 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-H. pylori treatment at baseline
Number of subjects: 795
Study 28647684 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous H. pylori infection for 16 years
Number of subjects: 795
Study 28647684 — intervention group
Group type: EXPERIMENTAL
Intervention: Incomplete-type IM
Number of subjects: 795
Study 28647684 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative time of infection
Number of subjects: 795
Study 25521438 — intervention group
Group type: EXPERIMENTAL
Intervention: State mandated private insurance coverage of CRC screening
Number of subjects: 0
Study 25521438 — intervention group
Group type: COMPARATOR
Intervention: No mandate
Number of subjects: 0
Study 24600204 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan (20 mg once daily for 16 weeks)
Number of subjects: 317
Study 24600204 — intervention group
Group type: COMPARATOR
Intervention: Candesartan (8 mg once daily for 16 weeks)
Number of subjects: 317
Study 24600204 — intervention group
Group type: COMPARATOR
Intervention: Telmisartan (40 mg once daily for 16 weeks)
Number of subjects: 317
Study 22257505 — intervention group
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training using Threshold IMT device (G-1; n = 16)
Number of subjects: 41
Study 22257505 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback (G-2; n = 15)
Number of subjects: 41
Study 22257505 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 10)
Number of subjects: 41
Study 19963436 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine 75 mg daily
Number of subjects: 311
Study 19963436 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyproterone acetate 100 mg daily
Number of subjects: 311
Study 19963436 — intervention group
Group type: EXPERIMENTAL
Intervention: Medroxyprogesterone acetate 20 mg daily
Number of subjects: 311
Study 18295343 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine switch (mean dose=290.0 mg/day, S.D.=55.2)
Number of subjects: 42
Study 18295343 — intervention group
Group type: COMPARATOR
Intervention: Risperidone continuation (mean dose=4.1 mg/day, S.D.=1.2)
Number of subjects: 42
Study 15993359 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microg Diamyd
Number of subjects: 47
Study 15993359 — intervention group
Group type: EXPERIMENTAL
Intervention: 500 microg Diamyd
Number of subjects: 47
Study 15993359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 15993359 — intervention group
Group type: EXPERIMENTAL
Intervention: All dose groups
Number of subjects: 47
Study 11485375 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA alone
Number of subjects: 15
Study 11485375 — intervention group
Group type: COMPARATOR
Intervention: BQ-123 alone
Number of subjects: 15
Study 11485375 — intervention group
Group type: EXPERIMENTAL
Intervention: L-NMMA with BQ-123
Number of subjects: 15
Study 9988537 — intervention group
Group type: EXPERIMENTAL
Intervention: liarozole
Number of subjects: 20
Study 9988537 — intervention group
Group type: COMPARATOR
Intervention: acitretin
Number of subjects: 20
Study 7906104 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular diclofenac sodium 1 mg.kg‐1
Number of subjects: 250
Study 7906104 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal bupivacaine 0.25% 1 ml.kg‐1
Number of subjects: 250
Study 7906104 — intervention group
Group type: COMPARATOR
Intervention: Control group (no analgesia)
Number of subjects: 250
Study 3134208 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime sodium carbonate
Number of subjects: 100
Study 3134208 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime arginine
Number of subjects: 100
Study 1870380 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of rifampicin 1500 mg followed by one year of daily dapsone 100 mg
Number of subjects: 0
Study 1870380 — intervention group
Group type: COMPARATOR
Intervention: Single dose of rifampicin 40 mg/K bodyweight
Number of subjects: 0
Study 320956 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium carbonate (mean serum level 0.91 mEq/liter)
Number of subjects: 23
Study 320956 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 31509979 — intervention group
Group type: EXPERIMENTAL
Intervention: Raw Orange (RO)
Number of subjects: 20
Study 31509979 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% Fresh Orange Juice (FOJ)
Number of subjects: 20
Study 31509979 — intervention group
Group type: EXPERIMENTAL
Intervention: Nectar-Sweetened Orange Juice (NSOJ)
Number of subjects: 20
Study 28666463 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive treatment by homeopaths
Number of subjects: 566
Study 28666463 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 566
Study 26460291 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 821
Study 23965181 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux 2.5 mg once daily
Number of subjects: 1349
Study 23965181 — intervention group
Group type: COMPARATOR
Intervention: Nadroparin 2850 anti-factor Xa IU once daily
Number of subjects: 1349
Study 23965181 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux
Number of subjects: 1349
Study 23965181 — intervention group
Group type: COMPARATOR
Intervention: Nadroparin
Number of subjects: 1349
Study 21862001 — intervention group
Group type: COMPARATOR
Intervention: Mock TEAS treatment (group I, n = 99)
Number of subjects: 309
Study 21862001 — intervention group
Group type: EXPERIMENTAL
Intervention: Single TEAS treatment (group II, n = 110)
Number of subjects: 309
Study 21862001 — intervention group
Group type: EXPERIMENTAL
Intervention: Double TEAS treatments (group III, n = 100)
Number of subjects: 309
Study 19363330 — intervention group
Group type: EXPERIMENTAL
Intervention: PI/r and NNRTI
Number of subjects: 71
Study 19363330 — intervention group
Group type: EXPERIMENTAL
Intervention: PI/r and NRTIs
Number of subjects: 71
Study 19363330 — intervention group
Group type: COMPARATOR
Intervention: NNRTI and NRTIs
Number of subjects: 71
Study 17805062 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan (60 mg/m2) and Cisplatin (75 mg/m2)
Number of subjects: 46
Study 17805062 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential Docetaxel (75 mg/m2)
Number of subjects: 46
Study 17805062 — intervention group
Group type: EXPERIMENTAL
Intervention: Irinotecan and Cisplatin (IC)
Number of subjects: 46
Study 17805062 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential Docetaxel
Number of subjects: 46
Study 15070418 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate 1 mg/kg/day + zinc sulfate 55 mg/day (with approximately 15 mg zinc element)
Number of subjects: 44
Study 15070418 — intervention group
Group type: COMPARATOR
Intervention: Methylphenidate 1 mg/kg/day + placebo (sucrose 55 mg)
Number of subjects: 44
Study 12227888 — intervention group
Group type: EXPERIMENTAL
Intervention: Triptorelin (Decapeptyl) and goserelin (Zoladex) - GnRH agonists, 4-month treatment course
Number of subjects: 52
Study 12227888 — intervention group
Group type: COMPARATOR
Intervention: Control group - untreated patients
Number of subjects: 52
Study 15010722 — intervention group
Group type: EXPERIMENTAL
Intervention: Zafirlukast (20 mg twice daily)
Number of subjects: 0
Study 15010722 — intervention group
Group type: EXPERIMENTAL
Intervention: Pranlukast (450 mg twice daily)
Number of subjects: 0
Study 15010722 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 0
Study 15010722 — intervention group
Group type: EXPERIMENTAL
Intervention: Zileuton (leukotriene synthesis inhibitor)
Number of subjects: 0
Study 15010722 — intervention group
Group type: EXPERIMENTAL
Intervention: PDE inhibitors
Number of subjects: 0
Study 7722992 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment matching process assessment
Number of subjects: 0
Study 2513206 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 160 mg/day
Number of subjects: 12
Study 2513206 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem 240 mg/day
Number of subjects: 12
Study 2513206 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine 80 mg/day
Number of subjects: 12
Study 2513206 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 40 to 80 mg/day
Number of subjects: 12
Study 2513206 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 320 mg/day
Number of subjects: 12
Study 2513206 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 5303665 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: one dose of 1 ml of cholera El Tor vaccine containing 8 x 10(9) organisms/ml
Number of subjects: 359600
Study 5303665 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: 2 doses (1 ml each) of cholera El Tor vaccine containing 8 x 10(9) organisms/ml
Number of subjects: 359600
Study 5303665 — intervention group
Group type: EXPERIMENTAL
Intervention: Group C: one dose of cholera El Tor vaccine containing 16 x 10(9) organisms/ml
Number of subjects: 359600
Study 5303665 — intervention group
Group type: COMPARATOR
Intervention: Group D: 2 doses of typhoid vaccine
Number of subjects: 359600
Study 31862217 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block (ESPB)
Number of subjects: 80
Study 31862217 — intervention group
Group type: COMPARATOR
Intervention: Quadratus Lumborum block type II (QLB‐II)
Number of subjects: 80
Study 31221888 — intervention group
Group type: EXPERIMENTAL
Intervention: rhinothermy delivered by nasal high flow therapy (rNHF) at 41°C for 2 hours daily for five days
Number of subjects: 170
Study 31221888 — intervention group
Group type: COMPARATOR
Intervention: sham rhinothermy for five days
Number of subjects: 170
Study 27883211 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortical porcine bone (cort)
Number of subjects: 90
Study 27883211 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagenated cortico‐cancellous (coll)
Number of subjects: 90
Study 27883211 — intervention group
Group type: COMPARATOR
Intervention: Natural healing (nat)
Number of subjects: 90
Study 26307618 — intervention group
Group type: EXPERIMENTAL
Intervention: GoActive intervention
Number of subjects: 31
Study 23874533 — intervention group
Group type: EXPERIMENTAL
Intervention: Nei Yang Gong (experimental group)
Number of subjects: 46
Study 23874533 — intervention group
Group type: COMPARATOR
Intervention: Progressive Muscle Relaxation (PMR) (control group)
Number of subjects: 46
Study 21810497 — intervention group
Group type: EXPERIMENTAL
Intervention: Harmonic Focus
Number of subjects: 34
Study 21810497 — intervention group
Group type: COMPARATOR
Intervention: Clamp-and-tie technique
Number of subjects: 34
Study 19254600 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task training with fixed-priority instructions
Number of subjects: 23
Study 19254600 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-task training with variable-priority instructions
Number of subjects: 23
Study 19254600 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-task training
Number of subjects: 23
Study 19254600 — intervention group
Group type: COMPARATOR
Intervention: All groups (including control)
Number of subjects: 23
Study 16708634 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural coffee (unfiltered)
Number of subjects: 36
Study 16708634 — intervention group
Group type: COMPARATOR
Intervention: Modified coffee (with reduced irritants)
Number of subjects: 36